Search
Chairs and members
Chair (2024–2027 term)Igor Aurer (education and scientific meetings co-lead) – University Hospital Centre Zagreb, University of Zagreb and KroHem, Croatia
Co-chair (2024–2027 term)Martin Dreyling (guidelines lead) – University Hospital Grosshadern, Ludwig Maximilian University and GLA, Germany
SWG Executive Board members (2024–2027 term)
Kim Linton (scientific secretary) –…
Chairs and Members
Chair (re-appointment, 2023–2026)Josef Vormoor—Professor of Hematological Malignancies in Children, University Medical Center Utrecht (The Netherlands)
Co-chair (re-appointment, 2023–2026)Maria Ester Bernardo—Clinical Coordinator, Clinical Research Unit, San Raffaele Telethon Institute for Gene Therapy (Italy)
SWG Steering Committee members (2024–2027 term)
SWG Secretary—Francesco Saglio, AOU Città…
Annual reports
EHA Annual Report 2023You can access an interactive version of our most recent annual report using the link below. Read the EHA Annual Report 2023
Previous annual reportsYou can read annual reports from previous years as PDFs.
SWG Educational Activities
General meetings in 2023Meetings to discuss the progress and management of collaborations within the European networks.
Read moreSpotlight on...
We talk to leaders, thinkers and influencers to hear their thoughts on #changeOfMindset #HotInHematology to provide a #VisionOfYourFuture.
Read moreOverview of EHA's Hemoglobinopathies Initiatives
The EHA Topics-in-Focus Hemoglobinopathies Program (focus on Sickle Cell Disease) aims to expand awareness and education about these increasingly common genetic diseases in Europe, among healthcare professionals, patients and the general population.
Read moreSWG Educational Activities
EHA2023 Hybrid CongressDate and locationJune 8–11, 2023, in Frankfurt, Germany. ChairMarie Jose Kersten
Case discussions
Follicular Lymphoma: Martin Dreylng, Daphne De Jong. Double hit Lymphoma: Andrew Davies, Elias Campo. T-follicular helper cell lymphoma: Andrew Davies, Daphne De Jong.
Meeting program
October 11, 2023 at 3 pm CET The interaction of von Willebrand factor (VWF) with platelet glycoprotein Ib: pathological implications and clinical manifestations
15:00-15:10 Introduction Giancarlo Castaman, Paolo Gresele …
EHA Ranking 2025
The information on this page is also available as a printable PDF. EHA Ranking 2025 — PDF version
Position
Company
Priority points
Corporate Level
1
Johnson & Johnson
1. 488,82
Platinum
2
Bristol Myers Squibb
1.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- »